Episode
Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
- Published
- Apr 1, 2026
- Duration seconds
- 1490
- Processing state
not_requested- Canonical source
- https://oncologytoday.captivate.fm/episode/5616-ashitp25-micro4
Actions
POST https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/immune-thrombocytopenia-microlearning-activity-4-with-dr-hanny-al-samkari-ash-2025-review/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/immune-thrombocytopenia-microlearning-activity-4-with-dr-hanny-al-samkari-ash-2025-review.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia. CME information and select publications here .